Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multi-center, Phase Ⅱ Clinical Study of Fluzoparib Combined With Apatinib or Fluzoparib in the Treatment of Metastatic Castration-resistant Prostate Cancer

NCT04869488 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT04869488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04869488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multi-center, Phase Ⅱ Clinical Study of Fluzoparib Combined With Apatinib or Fluzoparib in the Treatment of Metastatic Castration-resistant Prostate Cancer
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 19, 2021
Completion date
February 14, 2023
Enrollment
93 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer